The trial was discontinued due to sponsor's decision and not a consequence of any safety concern.

A Phase 1 dose-finding study of Universal Chimeric Antigen Receptor T-cells targeting cluster of differentiation (CD) 123 (UCART123) administered intravenously to patients with relapsed or refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), followed by a dose expansion phase in relapsed or refractory BPDCN patients or newly diagnosed BPDCN patients.

Main Inclusion Criteria:

• Patients with a diagnosis BPDCN according to World Health Organization (WHO) classification confirmed by hematopathology;
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1;